Moreover, preclinical studies have found that HDAC inhibitors (HDACis) are able to inhibit ovarian cancer cell growth in vitro and in vivo by inhibiting the cell cycle and inducing mitotic defects through histone-mediated and histone-independent interactions [30]. The gene discussed is HDAC9; the disease is ovarian carcinoma.